AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
- Sanofi and REVOLUTION Medicines launch global partnership to develop potential first-in-class targeted treatments for multiple cancers
- Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy
- Amgen and MBC Biolabs announce winners of the Amgen Golden Ticket
- Pfizer to organize for future growth
Research & Development
- Chemists characterize the fatal fungus among us
- Discovery of kidney cancer driver could lead to new treatment strategy
- New findings suggest allergic responses may protect against skin cancer
- The immune system: T cells are built for speed
- Bioengineers create pathway to personalized medicine
- Short-term improved vascular function after consuming red raspberries
- Human clinical trial reveals verapamil as an effective type 1 diabetes therapy
Conferences & Events
- Lyophilization USA Conference 2018
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
- SMi presents the 9th Conference on Biosimilars & Biobetters
Regulatory Affairs
- FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
- FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
- FDA warns of imposters sending consumers fake warning letters
- FDA takes steps to encourage more informative labeling on prescription drug and biological products' indications and usage
- FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
- FDA takes steps to foster greater efficiency in biosimilar development by reconsidering draft guidance on evaluating analytical studies
- FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales